Novo Nordisk A/S and Janssen Biotech, Inc. have signed an agreement that will allow Janssen to acquire an exclusive global license to further develop and commercialize a clinical program focused on therapy within autoimmune diseases. The program targets modulation of certain immune cells via a cell surface receptor (NKG2D receptor), according to Novo Nordisk.
The agreement still requires final clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission.
Terms of the agreement have not been released.
Source: Novo Nordisk